Efficacy and safety of TAS-102 plus Surufatinib in third and later line metastatic pancreatic cancer: a prospective, single center and biomarker exploratory, phase II study
TAS-102联合苏鲁替尼治疗三线及后续转移性胰腺癌的疗效和安全性:一项前瞻性、单中心、生物标志物探索性II期研究
期刊:Molecular Cancer
影响因子:33.9
doi:10.1186/s12943-025-02437-0
Lu, Yunxin; Lin, Qingguang; Mo, Yongxin; Liu, Furong; Zhang, Mengwei; Huang, Runjie; Wang, Yun; Wang, Yinnan; Wang, Zhiqiang; Luo, Huiyan; Guo, Guifang; Chen, Jianwen; Liu, Yu; He, Mingming; Wang, Fenghua; Wang, Feng; Zhang, Dongsheng